领导团队

Christopher Simon 于 2016 年 5 月 16 日被任命为 CEO。此前他曾担任 McKinsey & Company 的资深合伙人并领导 Global Medical Products Practice（全球医疗产品实践）部门。他在促进公司业务改革和 发展 方面拥有超过二十年的经验。

Chris 在 2015 年 10 月启动的战略评审中作为 Haemonetics 的主要合作伙伴，深入了解了公司业务和市场。他与管理层及董事会共同制定了当前正在实施的战略计划。

他自 1993 年以来一直在 McKinsey 工作，而在此之前，他曾在 Baxter Healthcare Corporation 担任商务和运营职位，以及在韩国担任美国第 1 游骑兵营的陆军步兵军官。

Chris 从宾夕法尼亚大学沃顿学院获得经济学理学士学位，以及从哈佛大学商学院获得 MBA 学位。

Michelle Basil joined Haemonetics in March 2017 as Executive Vice President, General Counsel. She is responsible for Haemonetics' Legal, Compliance and Corporate Audits and Controls groups.

Prior to joining Haemonetics, Ms. Basil was a Partner and Chair of the Life Sciences Practice Group at the Boston-based law firm Nutter, McClennen & Fish where she was legal counsel to public and private companies and their investors, principally in the life sciences and medical technology industries. At Nutter, Ms. Basil’s practice focused on corporate and securities law, including mergers and acquisitions, strategic collaborations, capital markets transactions, corporate governance and other matters affecting publicly traded companies and their officers and directors.

Ms. Basil is admitted to the bar in Massachusetts and holds both a Bachelor of Arts and a Juris Doctor from the University of California at Berkeley.

Bill Burke 于 2016 年 8 月加入 Haemonetics，担任首席财务官，对包括投资者关系在内的全球财务机构负责。Burke 先生之前曾任首席整合官和副总裁，对 Medtronic / Covidien 的合并进行整合。Burke 先生在担任目前的职位之前，曾在 Covidien 工作九年多，担任各种财务领导职位，包括：欧洲首席财务官，公司战略与组合管理副总裁，FP&A 副总裁。在 Covidien 之前，他曾在 FP&A 担任数个职位，曾任 Tyco Healthcare Group 的公司审计员。Burke 先生持有布赖恩特学院工商管理理学学士学位，主修会计学，此外，Bill 还是注册会计师 (CPA)。

David Gueundjian joined Haemonetics in March 2017, bringing nearly 30 years of international experience living and working in various countries across Europe, Asia and Latin America, and leading organizations through transformation to drive business excellence and growth.

Previously, Mr. Gueundjian worked for Ferring Pharmaceuticals, where he managed the Mid-Europe region and led the commercial, market development and medical operations group for Europe and Canada. Prior to that, he held multiple regional leadership roles at Edwards LifeSciences, including Vice President and General Manager, Cardiovascular Therapies for Japan, Vice President and General Manager, Heart Valve Therapy for Europe (EMEA), and Vice President and General Manager for Latin America. Before focusing his time and efforts in medical devices and pharmaceuticals, Mr. Gueundjian spent the first part of his career in organizational effectiveness and talent management consulting, most notably in leadership roles with Hewitt Associates in Europe and Asia.

Carter Houghton joined Haemonetics in December 2016 as President, Hospital Business Unit. He is a highly accomplished leader with a deep knowledge of the hospital segment and a track record of turning around and growing healthcare businesses.

Mr. Houghton’s experience spans division leadership, product marketing and business development roles at Hologic, Inc., where most recently he served as Senior Vice President and General Manager, GYN Surgical Solutions. Prior to Hologic he held various roles of increasing responsibility at Verrillon and Corning, Inc. During his time at Corning, Mr. Houghton spent five years in the Company’s Clinical Labs Division which was later spun off into Quest Diagnostics.

Mr. Houghton holds an MBA from the University of Virginia's Darden School of Business, and a Bachelor of Arts in Journalism and History from the University of Richmond. He also completed an executive education program in Negotiation from the Said Business School at Oxford University.

Chad Nikel joined Haemonetics in 2009 as Site Director for the company’s Illinois facility, where he managed TEG operations, research and development, and marketing. In April 2011, he was promoted to Vice President, Global TEG, where he chartered a team in the global launch of the TEG product line and led an initiative to acquire a next generation technology for hemostasis monitoring. Mr. Nikel was promoted to Vice President, North America Blood Bank in September 2013, where he led commercial activities for the company’s Blood Center business and assumed global responsibility for the Whole Blood business in 2015. Mr. Nikel was promoted to Vice President, Global Blood Center, in 2017 and to his current role as President, Global Blood Center, in 2018.

Prior to joining Haemonetics, Mr. Nikel was Director, Strategy and Business Development at IPM Life Sciences. He previously held roles in research and development, operations and project management. Mr. Nikel began his career in the United States Air Force, where he served for five years and earned the rank of Captain.

Mr. Nikel holds a Bachelor of Science in both Civil Engineering and Environmental Engineering from the United States Air Force Academy and an MBA from St. Mary’s University.

Kevin O’Kelly-Lynch joined Haemonetics in December 2016 as Senior Vice President, Global Business Services. He has an extensive and seasoned background in global business and shared services spanning customer service and tech support, finance, procurement, IT, fleet and sales operations. He brings to Haemonetics the knowledge and experience to help the company successfully transform the way it creates enabling platforms to deliver critical services across multiple functions.

Mr. O’Kelly-Lynch most recently served as Vice President, Medtronic Business Services, where he led the Global Business Services Integration activity post the acquisition of Covidien, and managed a service delivery team of over 600 deployed in the United States, Europe and India. Prior to Medtronic, he was Vice President, Assistant Treasurer at Covidien plc, where he was responsible for global treasury operations. He has also held the position of International Treasurer & Managing Director at Tyco International, and Transfer Pricing Manager and Management Accountant at Diageo plc. He began his career at Fujitsu.

Mr. O’Kelly-Lynch received a Bachelor of Science in Management from Trinity College, Dublin and is a Chartered Global Management Accountant (CGMA).

Ian Purdy, Ph.D., joined Haemonetics in March 2017 as Senior Vice President, Global Quality and Regulatory Affairs. He is responsible for Haemonetics' global quality programs and regulatory product approvals and agency relationships.

Dr. Purdy has more than 20 years of experience in medical devices and diagnostics spanning all regions of the world, along with extensive experience in new product submissions, particularly in China, Europe, Japan and the U.S.

Most recently, he was Vice President, Clinical Regulatory and Quality Compliance at Thermo Fisher Scientific since 2012. He was responsible for the oversight and coordination of worldwide regulatory and quality compliance, overseeing a team of 2,500 employees at more than 100 global sites. He also held numerous clinical, regulatory and quality roles of increasing scope at Boston Scientific between 2000 and 2012, playing a critical role in ensuring regulatory and quality excellence for innovation-based products. He began his career working in clinical research at Smiths Medical.

Dr. Purdy holds a doctorate in Human Physiology (Haemodynamics) from the University of Southampton in the U.K., an expertise that is highly relevant to many of Haemonetics’ products and programs.

Neil Ryding 于 2015 加入 Haemonetics，担任全球运营执行副总裁。加入 Haemonetics 之前的 30 多年里，Ryding 先生在航天和医疗设备行业的受监管领域内任职于若干领先全球的跨国制造企业和供应链组织。在许多综合性跨国公司里，包括 Rolls Royce Aero-Engines、Johnson & Johnson、Smith & Nephew、Cardinal Health 和 Hospira，他担任过多种需要广博运营知识和综合能力的职务，足迹遍及全球。

Jacqueline Scanlan joined Haemonetics in March 2017 as Senior Vice President, Human Resources. She is responsible for the global Human Resources and Communications functions, with a focus on driving talent management.

Previously, Ms. Scanlan was Corporate Vice President, Human Resources, North America at Novo Nordisk. In this role, she led all aspects of the organization and people strategy for North America, and served as a key member of the Executive Team. Her responsibilities included organization development as well as change and talent management. Prior to Novo Nordisk, she held various HR leadership roles at Campbell Soup Company, including International HR, Global Talent Management and Organizational Effectiveness, and HR Business Partner. Earlier in her career, Ms. Scanlan held HR and consulting roles at Bristol-Myers Squibb, DuPont Pharmaceuticals Company and Accenture.

Ms. Scanlan received a Bachelor of Arts in Political Science from St. Joseph’s University and a Master of Science in Organizational Dynamics from the University of Pennsylvania.

Francis “Frank” Tan joined Haemonetics in June 2017 as Senior Vice President, Corporate Development and Planning. He is responsible for all of Haemonetics’ business development activities, including partnerships, collaborations, and mergers and acquisitions.

Previously, Mr. Tan was Vice President, Corporate Development at Thermo Fisher Scientific. While there, he developed and executed strategic growth initiatives across the company’s multiple businesses, representing roughly $18 billion in total revenues. He also led the execution of over a dozen merger and acquisition transactions valued at more than $30 billion. Prior to Thermo Fisher, Mr. Tan was Director, Business Development at EMD Millipore and held leadership roles in the company’s integration office during Millipore’s acquisition by Merck KGaA. He has an extensive background across all types of external licensing and partnership relationships as well as corporate strategy, product management, private equity, and financial analysis.

Mr. Tan holds a Bachelor of Arts from Amherst College and an MBA in Finance and Strategy from the Yale School of Management.

David J. Wilson joined Haemonetics in September 2017 as President, Global Plasma. He is a proven business leader with more than 20 years of experience in senior leadership roles at medical technology companies. He is responsible for expanding and strengthening the company’s market position in the plasma industry.

Mr. Wilson was most recently President, Cordis (a Cardinal Health company), which he led from March 2015 through August 2017. Cordis is a nearly $1 billion business focused on cardiovascular devices that Mr. Wilson brought back to profitable sales growth during his tenure as President. Prior to Cordis, Mr. Wilson held positions of increasing responsibility at Johnson & Johnson driving sales, marketing, research and development, operations and business development. He also worked previously in plasma-based sciences both at Ethicon Biosurgery and at Cohesion Corporation.

Mr. Wilson received a Bachelor of Mechanical Engineering from Auburn University, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham, and an MBA from Columbia University.